ArticleCommunications biology2026
Anthraquinones derived from soil actinomycetes combat multidrug-resistant Staphylococcus aureus.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global spread of multidrug-resistant Staphylococcus aureus (MRSA) poses serious threats to public health and food safety. In this study, the antibacterial potential of the anthraquinone compound 13394-2, derived from soil actinomycetes, was systematically evaluated. In vitro, 13394-2 exhibited potent activity (MIC as low as 0.25 μg/mL), rapid bactericidal effects, biofilm clearance, and concentration-dependent killing. Mechanistic studies revealed that membrane disruption, ROS accumulation, and ATP depletion are key bactericidal pathways leading to metabolic collapse. Transcriptomic, computational analyses and biophysical experiments revealed significant interference with protein, energy, and fatty acid metabolism, with FabF identified as a potential target. Toxicity assessments confirmed low cytotoxicity and good in vivo safety. In animal infection models, 13394-2 improved survival, reduced bacterial burden and tissue damage, and promoted wound healing. It also effectively eliminated drug-resistant S. aureus in simulated food and surface contamination models. These findings support the potential of anthraquinones as potential antibiotics against drug-resistant infections and environmental contamination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.